Cardiomyocytes induced from hiPSCs by well-defined compounds have therapeutic potential in heart failure by secreting PDGF-BB
Tóm tắt
Recent studies have suggested that transplant of hiPS-CMs is a promising approach for treating heart failure. However, the optimally clinical benefits have been hampered by the immature nature of the hiPS-CMs, and the hiPS-CMs-secreted proteins contributing to the repair of cardiomyocytes remain largely unidentified. Here, we established a saponin+ compound optimally induced system to generate hiPS-CMs with stable functional attributes in vitro and transplanted in heart failure mice. Our study showed enhanced therapeutic effects of optimally induced hiPS-CMs by attenuating cardiac remodeling and dysfunction, these beneficial effects were concomitant with reduced cardiomyocytes death and increased angiogenesis. Moreover, the optimally induced hiPS-CMs could gathering to the injured heart and secret an abundant PDGF-BB. The reparative effect of the optimally induced hiPS-CMs in the hypoxia-injured HCMs was mimicked by PDGF-BB but inhibited by PDGF-BB neutralizing antibody, which was accompanied by the changed expression of p-PI3K and p-Akt proteins. It is highly possible that the PI3K/Akt pathway is regulated by the PDGF-BB secreted from the compound induced hiPS-CMs to achieve a longer lasting myocardial repair effect compared with the standard induced hiPS-CMs. Taken together, our data strongly implicate that the compound induced hiPS-CMs promote the recovery of injured hearts via paracrine action. In this process, the paracrine factor PDGF-BB derived from the compound induced hiPS-CMs reduces isoproterenol-induced adverse cardiac remodeling, which is associated with improved cardiac function, and these effects are mediated by the PI3K/Akt pathway, suggesting that the optimally induced hiPS-CMs may serve as a new promising cell therapy for clinical applications.
Từ khóa
Tài liệu tham khảo
Menasché, P. & Vanneaux, V. Stem cells for the treatment of heart failure. Curr. Res. Transl. Med. 64, 97–106 (2016).
Litwinowicz, R. et al. The use of stem cells in ischemic heart disease treatment. Kardiochir. Torakochirurgia. Pol. 15, 196–199 (2018).
Yoon, Y. S. et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J. Clin. Invest. 115, 326–338 (2005).
Seidel, M. et al. Cell-based therapy for heart failure: skeletal myoblasts. Cell. Transplant. 18, 695–707 (2009).
Michler, R. E. The current status of stem cell therapy in ischemic heart disease. J. Card. Surg. 33, 520–531 (2018).
Nguyen, P. K., Rhee, J. W. & Wu, J. C. Adult stem cell therapy and heart failure, 2000 to 2016: a systematic review. JAMA Cardiol. 1, 1831–1841 (2016).
Poulin, M. F., Deka, A., Mohamedali, B. & Schaer, G. L. Clinical benefits of stem cells for chronic symptomatic systolic heart failure: a systematic review of the existing data and ongoing trials. Cell. Transplant. 25, 1911–1923 (2016).
Wu, D. C., Boyd, A. S. & Wood, K. J. Embryonic stem cells and their differentiated derivatives have a fragile immune privilege but still represent novel targets of immune attack. Stem Cells 26, 1939–1950 (2008).
Masumoto, H. & Yamashita, J. K. Human iPS cell-engineered three-dimensional cardiac tissues perfused by capillary networks between host and graft. Inflamm. Regen. 10, 26 (2018).
Nelson, T. J. & Terzic, A. Induced pluripotent stem cells: an emerging theranostics platform. Clin. Pharmacol. Ther. 89, 648–650 (2011).
Shiba, Y. et al. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature 538, 388–391 (2016).
Tohyama, S. et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 12, 127–137 (2013).
Wu, F. F. et al. Generation of hepatobiliary organoids from human induced pluripotent stem cells. J. Hepatol. 70, 1145–1158 (2019).
Hartman, M. E., Dai, D. F. & Laflamme, M. A. Human pluripotent stem cells: prospects and challenges as a source of cardiomyocytes for in vitro modeling and cell-based cardiac repair. Adv. Drug. Deliv. Rev. 96, 3–17 (2016).
Ponikowski et al. Heart failure: preventing disease and death worldwide. Esc. Heart Fail. 1, 4–25 (2014).
Stoltz, J. F. et al. Organ reconstruction: dream or reality for the future. Biomed. Mater. Eng. 28, S121–S127 (2017).
Miyagawa, S. & Sawa, Y. Building a new strategy for treating heart failure using induced pluripotent stem cells. J. Cardiol. 72, 445–448 (2018).
Higuchi, T. et al. Functional and electrical integration of induced pluripotent stem cell-derived cardiomyocytes in a myocardial infarction rat heart. Cell Transpl. 24, 2479 (2015).
Willems, E. et al. Small-molecule inhibitors of the Wnt pathway potently promote cardiomyocytes from human embryonic stem cell-derived mesoderm. Circ. Res. 109, 360–364 (2011).
Hom, J. et al. The permeability transition pore controls cardiac mitochondrial maturation and myocyte differentiation. Dev. Cell 21, 469–478 (2011).
Winter, J. L. et al. Effects of trimetazidine in nonischemic heart failure: a randomized study. J. Card. Fail. 20, 149–154 (2014).
Hilfiker-Kleiner, D., Landmesser, U. & Drexler, H. Molecular mechanisms in heart failure: focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J. Am. Coll. Cardiol. 48, A56–A66 (2006).
Sampsa, P. et al. GATA transcription factors in the developing and adult heart. Cardiovasc. Res. 63, 196–207 (2004).
Akazawa, H. & Komuro, I. Cardiac transcription factor Csx/Nkx2-5: Its role in cardiac development and diseases. Pharmacol. Therapeut. 107, 252–268 (2005).
Aoki, M. et al. Therapeutic angiogenesis induced by HGF: Potential gene therapy for ischemic diseases. Atherosclerosis 151, 81–81 (2000).
Eschenhagen, T. et al. Cardiomyocyte regeneration: a consensus statement. Circulation 136, 680–686 (2017).
Vagnozzi, R. J., Maillet, M., Sargent, M. A., Khalil, H. & Molkentin, J. D. An acute immuneresponse underlies the benefit of cardiac stem-cell therapy. Nature 577, 405–409 (2019).
Kelner, G. S. et al. Lymphotactin: a cytokine that represents a new class of chemokine. Science 266, 1395–1399 (1994).
Lindsey, M. L. et al. Identifying the molecular and cellular signature of cardiac dilation following myocardial infarction. BBA-Mol. Basis. Dis. 1865, 1845–1852 (2019).
Matthias, L. et al. Local injection of stem cell factor (SCF) improves myocardial homing of systemically delivered c-kit + bone marrow-derived stem cells. Cardiovasc. Res. 1, 143–150 (2008).
Vantler, M. et al. PDGF-BB protects cardiomyocytes from apoptosis and improves contractile function of engineered heart tissue. J. Mol. Cell Cardiol. 48, 1316–1323 (2010).
Hasegawa, H. et al. Cardioprotective effects of granulocyte colony-stimulating factor in swine with chronic myocardial ischemia. J. Am. Coll. Cardiol. 47, 842–849 (2006).
Shiojima, I. et al. Role of akt signaling in vascular homeostasis and angiogenesis. Circ. Res. 90, 1243–1250 (2002).